Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia

Etsay Weldekidan Tsegay,1 Desalegn Getnet Demise,1 Nigus Alemu Hailu,2 Zenawi Hagos Gufue3 1Department of Pharmacy, College of Medicine and Health Sciences, Adigrat University, Adigrat, Tigray, Ethiopia; 2Department of Biomedical Science, College of Medicine and Health Sciences, Adigrat University,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tsegay EW, Demise DG, Hailu NA, Gufue ZH
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	serotonin 6 receptor serotonin 7 receptor agonist antagonist schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a89891def74448d187250b78096cc001
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a89891def74448d187250b78096cc001
record_format	dspace
spelling	oai:doaj.org-article:a89891def74448d187250b78096cc0012021-12-02T13:10:09ZSerotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia1178-2021https://doaj.org/article/a89891def74448d187250b78096cc0012020-10-01T00:00:00Zhttps://www.dovepress.com/serotonin-type-6-and-7-receptors-as-a-novel-therapeutic-target-for-the-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Etsay Weldekidan Tsegay,1 Desalegn Getnet Demise,1 Nigus Alemu Hailu,2 Zenawi Hagos Gufue3 1Department of Pharmacy, College of Medicine and Health Sciences, Adigrat University, Adigrat, Tigray, Ethiopia; 2Department of Biomedical Science, College of Medicine and Health Sciences, Adigrat University, Adigrat, Tigray, Ethiopia; 3Department of Public Health, College of Medicine and Health Sciences, Adigrat University, Adigrat, Tigray, EthiopiaCorrespondence: Etsay Weldekidan TsegayDepartment of Pharmacy, College of Medicine and Health Sciences, Adigrat University, PO Box 50, Adigrat, EthiopiaTel +251-929263029Email etsay065@gmail.comAbstract: Schizophrenia is a serious disease of the central nervous system that affects a person’s ability to think, feel and behave clearly. Even though the pathophysiological hypothesis of the disease is not clearly understood, dysfunction of dopamine, glutamate, serotonin and other neurotransmitters is widely believed to be involved. Serotonin within the synaptic vesicles functions as neurotransmitter and neurohormone in regulation of emotion, learning, memory, hormone release, cognition and motor function. Dysfunction of normal brain activity of serotonin is associated with schizophrenia. The role of serotonin 6 and 7 receptors in schizophrenia, interaction with neurotransmitters and the effect of drugs on those receptors in schizophrenia are the goal of this review. The aim of this review was to provide information for researchers and other scholars to identify the possible intervention points in the management of schizophrenia. The serotonin 6 and 7 receptors are associated with schizophrenia via modulating cyclic adenosine monophosphate, regulation of Fyn kinase and induction of structural plasticity. The above modulatory effects affect cholinergic, dopaminergic, glutamatergic, adrenergic and GABAergic systems. Recently, diverse numbers of selective agonist and antagonist ligands were developed for both receptors. SGS-518, ABT-354, Lu AE58054, SB-742,457, S-518, AVN-211, AVN-322, SYN-114 and SYN-120 are serotonin 6 receptor antagonists and aripiprazole-controlled release serotonin 7 receptor agonists under clinical trial for schizophrenia. Thus, research on novel drugs that act on serotonin 6 and 7 receptors likely facilitates the intervention into schizophrenia patients seeking better quality of life in the future.Keywords: serotonin 6 receptor, serotonin 7 receptor, agonist, antagonist, schizophreniaTsegay EWDemise DGHailu NAGufue ZHDove Medical Pressarticleserotonin 6 receptorserotonin 7 receptoragonistantagonistschizophreniaNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 16, Pp 2499-2509 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	serotonin 6 receptor serotonin 7 receptor agonist antagonist schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	serotonin 6 receptor serotonin 7 receptor agonist antagonist schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Tsegay EW Demise DG Hailu NA Gufue ZH Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia
description	Etsay Weldekidan Tsegay,1 Desalegn Getnet Demise,1 Nigus Alemu Hailu,2 Zenawi Hagos Gufue3 1Department of Pharmacy, College of Medicine and Health Sciences, Adigrat University, Adigrat, Tigray, Ethiopia; 2Department of Biomedical Science, College of Medicine and Health Sciences, Adigrat University, Adigrat, Tigray, Ethiopia; 3Department of Public Health, College of Medicine and Health Sciences, Adigrat University, Adigrat, Tigray, EthiopiaCorrespondence: Etsay Weldekidan TsegayDepartment of Pharmacy, College of Medicine and Health Sciences, Adigrat University, PO Box 50, Adigrat, EthiopiaTel +251-929263029Email etsay065@gmail.comAbstract: Schizophrenia is a serious disease of the central nervous system that affects a person’s ability to think, feel and behave clearly. Even though the pathophysiological hypothesis of the disease is not clearly understood, dysfunction of dopamine, glutamate, serotonin and other neurotransmitters is widely believed to be involved. Serotonin within the synaptic vesicles functions as neurotransmitter and neurohormone in regulation of emotion, learning, memory, hormone release, cognition and motor function. Dysfunction of normal brain activity of serotonin is associated with schizophrenia. The role of serotonin 6 and 7 receptors in schizophrenia, interaction with neurotransmitters and the effect of drugs on those receptors in schizophrenia are the goal of this review. The aim of this review was to provide information for researchers and other scholars to identify the possible intervention points in the management of schizophrenia. The serotonin 6 and 7 receptors are associated with schizophrenia via modulating cyclic adenosine monophosphate, regulation of Fyn kinase and induction of structural plasticity. The above modulatory effects affect cholinergic, dopaminergic, glutamatergic, adrenergic and GABAergic systems. Recently, diverse numbers of selective agonist and antagonist ligands were developed for both receptors. SGS-518, ABT-354, Lu AE58054, SB-742,457, S-518, AVN-211, AVN-322, SYN-114 and SYN-120 are serotonin 6 receptor antagonists and aripiprazole-controlled release serotonin 7 receptor agonists under clinical trial for schizophrenia. Thus, research on novel drugs that act on serotonin 6 and 7 receptors likely facilitates the intervention into schizophrenia patients seeking better quality of life in the future.Keywords: serotonin 6 receptor, serotonin 7 receptor, agonist, antagonist, schizophrenia
format	article
author	Tsegay EW Demise DG Hailu NA Gufue ZH
author_facet	Tsegay EW Demise DG Hailu NA Gufue ZH
author_sort	Tsegay EW
title	Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia
title_short	Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia
title_full	Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia
title_fullStr	Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia
title_full_unstemmed	Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia
title_sort	serotonin type 6 and 7 receptors as a novel therapeutic target for the treatment of schizophrenia
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/a89891def74448d187250b78096cc001
work_keys_str_mv	AT tsegayew serotonintype6and7receptorsasanoveltherapeutictargetforthetreatmentofschizophrenia AT demisedg serotonintype6and7receptorsasanoveltherapeutictargetforthetreatmentofschizophrenia AT hailuna serotonintype6and7receptorsasanoveltherapeutictargetforthetreatmentofschizophrenia AT gufuezh serotonintype6and7receptorsasanoveltherapeutictargetforthetreatmentofschizophrenia
_version_	1718393462935519232

Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia

Ejemplares similares